Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : withdraws pelvic mesh device from Australian market

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/23/2018 | 05:29am CET

Pharmaceutical giant Johnson & Johnson has withdrawn from the Australian market its supply of the vaginal mesh device that is the subject of a class action before the federal court.

On Tuesday a spokeswoman for Australia’s medical devices regulator, the Therapeutic Goods Administration, confirmed to Guardian Australia that the mid-urethral vaginal sling devices, used to treat stress urinary incontinence in women, were no longer being imported.

Related: What does pelvic mesh do and why are women suing over it? – explainer

The devices are produced by the Johnson & Johnson company Ethicon and no longer appear on the Australian Therapeutic Goods Register, which is a list of products that can be lawfully supplied in Australia. The TGA has not responded to questions about whether the removal of the products from the register also means that products already on hospital shelves cannot be used by surgeons.

The TGA asked all manufacturers of transvaginal sling and mesh devices to update the “instructions for use” on transvaginal mesh and tape products before 17 January to include information about possible adverse events such as severe chronic pain, groin pain and bladder perforation.

According to the TGA, Johnson & Johnson did not meet this deadline and withdrew the supply of their mid-urethral sling devices to enable them to consider their options. A list of pharmaceutical companies that have met the new requirements has been made public.

The president of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Professor Steve Robson, told Guardian Australia he had written to all members to alert them to the development. It was his understanding that Johnson & Johnson slings already on hospital shelves could still be used but new supplies could not be imported.

Robson said he did not have “exact figures”, but the Johnson & Johnson devices were probably the most widely used by surgeons to treat incontinence.

Related: Australia bans transvaginal mesh products as 'too risky'

“What I have heard is once the stock on the shelf is gone that’s it, and many hospitals, if not most, are looking at other options including other brands of urethral tape, which are still available,” Robson said.

“The feedback is some places are exploring transition arrangements so women can be offered other similar products. What I also wrote to our members yesterday was that it is clear mid-urethral tapes are the most appropriate response to incontinence which has not responded to other clinical treatment. We recirculated a Cochrane review that shows that mid-urethral tapes are the most appropriate treatment when used appropriately, and are very safe.

“In fact, I think it’s regrettable it won’t be available for a while, but there are other similar products.”

The Johnson & Johnson/Ethicon implant became the subject of a class action run by Shine Lawyers in 2017, with 700 Australian women alleging that faulty pelvic mesh implants caused them debilitating pain.

Similar class actions involving thousands of women are also under way in the UK and US. More than 100,000 transvaginal mesh lawsuits have been filed in the US, the largest number against Johnson & Johnson, the manufacturer of the most commonly used meshes. Shine Lawyers alleges Johnson & Johnson failed to properly test the devices and played down their risk to both surgeons and patients.

A Senate inquiry has examined whether any financial or other incentives have been provided to medical practitioners to use or promote transvaginal mesh implants; the lack of data available on how many procedures were performed; and the type and incidence of health problems woman have experienced.

The class action is due to return to the federal court in Sydney on Monday.

Johnson & Johnson has been contacted for comment.

Copyright © 2018 theguardian.com. All rights reserved., source Guardian Online

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
05:29a JOHNSON & JOHNSON : withdraws pelvic mesh device from Australian market
01/22 JOHNSON & JOHNSON : Business events scheduled for Tuesday
01/22 JOHNSON & JOHNSON : amended statement of beneficial ownership
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 Targovax appoints Michael Bogenstaetter as chief business officer
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
01/22 JOHNSON & JOHNSON : FDA grants Darzalex Priority Review for first-line MM
01/19 +43% CAGR TO BE ACHIEVED BY MHEALTH : MHealth Monitoring and Diagnostic Medical..
More news
News from SeekingAlpha
01/22 Notable earnings before Tuesday?s open
01/22 JOHNSON & JOHNSON : What's About To Happen?
01/22 Good, Tasty Total Return And Income For This Food Company
01/22 3M : A Fast-Growing Dividend King
01/22 Game Plan For The Week - Cramer's Mad Money (1/19/18)
Financials ($)
Sales 2017 76 331 M
EBIT 2017 22 977 M
Net income 2017 16 393 M
Debt 2017 16 791 M
Yield 2017 2,27%
P/E ratio 2017 24,79
P/E ratio 2018 20,56
EV / Sales 2017 5,41x
EV / Sales 2018 5,01x
Capitalization 396 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 148 $
Spread / Average Target 0,50%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132
AMGEN8.84%137 400